TCTR20221003002Unknown4 期
Effect of SGLT2 inhibitor on Renal Function and Urinary [TIMP-2] x [IGFBP7] in Patients Hospitalized for Acute Heart Failure; A Randomized Controlled Trail
/A0 个研究点目标入组 66 人开始时间: 2022年10月3日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •1. acute decompensated heart failure
- •1.1 dyspena at rest or dyspnea on minimal exertion
- •1.2 signs of pulmonary congestion
- •1.3 NT- proBNP more than 1600 pg/ml or more than 2000 pg/ml in atrial fibrillation patients
- •2. No vasodilator intravenous within 6 hours
- •3. No vasopressor and inotropic drug intravenous within 6 hours
排除标准
- •1. Type 1 diabetes
- •2. History of diabetic ketosis or ketosis
- •3. GFR (CKD-EPI) < 30 ml/min/1.73 square meter
- •4. History of prior SGLT2 inhibitor
- •5. Systolic blood pressure < 100 mmHg
- •6. Cardiogenic shock
- •7. History of percutaneous coronary intervention within 30 days before enrollment or planned for percutaneous coronary intervention
- •8. Immunosuppressive agent use
- •9. Acidemia with pH < 7.2
- •10. Sepsis or septic shock
- •11. Liver failure
- •12. Pregnancy or breast feeding
研究者
相似试验
招募中
Unknown
The Renal Protective Effect Of SGLT2 Inhibitor Drug In Diabetics Patient Who Are Undergoing Per cutaneous Coronary Interventions.CTRI/2023/10/058896GSM Institute of Pharmaceutical Science
进行中（未招募）
1 期
The RECEDE-CHF TrialType 2 diabetes and heart failureMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10010684Term: Congestive heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-003968-39-GBniversity of Dundee/NHS Tayside23
招募中
不适用
Investigation of renal protective effects of SGLT2 inhibitor by using renal doppler ultrasonographyJPRN-UMIN000028438Ogawa Red Cross Hospital60
已完成
4 期
Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome PreventionCongestive Heart FailureNCT04778787I.M. Sechenov First Moscow State Medical University370
已完成
3 期
Evaluation Renoprotective Effect SGLT2 inhibitors on Prognosis of Transplant Kidney PatientsCondition 1: Diabetes mellitus type 2. Condition 2: Transplant Kidney.Type 2 diabetes mellitus with kidney complicationsKidney transplant statusE11.2Z94.0IRCT20220708055414N1Orchidpharmed30